Invasive Breast Carcinoma Recruiting Phase 2 Trials for Doxorubicin (DB00997)
Also known as: Invasive carcinoma of breast / Breast cancer invasive NOS
Indication | Status | Phase |
---|---|---|
DBCOND0031787 (Invasive Breast Carcinoma) | Recruiting | 2 |
clinicaltrials.gov Identifier | Title | Purpose | Drugs |
---|---|---|---|
NCT02957968 | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | Treatment | |
NCT02456857 | Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative | Treatment | |
NCT01750073 | Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Breast Cancer | Treatment |